BRIEF published on 08/19/2026 at 20:40, 16 days 2 hours ago Revive Therapeutics Proposes Shares for Debt Settlement Debt Settlement Canadian Securities Exchange Shares Issuance Revive Therapeutics Biodefense Research
PRESS RELEASE published on 08/19/2026 at 20:35, 16 days 2 hours ago Revive Therapeutics Announces Proposed Shares for Debt Settlement Revive Therapeutics Ltd. announces proposed debt settlement by issuing Settlement Shares to settle outstanding trade payables. Subject to CSE approval Debt Settlement Settlement Shares CSE Approval Revive Therapeutics Ltd. Biodefence
BRIEF published on 08/19/2026 at 14:45, 16 days 8 hours ago Revive Therapeutics Advances Biodefence Strategy with Bucillamine Medical Countermeasures Pandemic Preparedness Government Partnerships Bucillamine Biodefence
PRESS RELEASE published on 08/19/2026 at 14:40, 16 days 8 hours ago Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio Revive plans to expand bucillamine use in biodefence with positive DRDC findings, government opportunities, and complementary therapies, focusing on medical countermeasures Bucillamine Biodefence Revive DRDC Government Opportunities
BRIEF published on 08/15/2026 at 00:55, 20 days 22 hours ago Revive Therapeutics Grants 15.5 Million Stock Options Stock Options Life Sciences Biodefense Pandemic Preparedness Revive Therapeutics
PRESS RELEASE published on 08/15/2026 at 00:50, 20 days 22 hours ago Revive Therapeutics Reports Grant of Options Revive Therapeutics Ltd. authorized the grant of 15,500,000 incentive stock options to key team members. The options aim to drive performance and incentivize excellence in advancing corporate objectives Stock Options Incentive Pandemic Preparedness Revive Therapeutics Ltd. Biodefence
BRIEF published on 08/12/2026 at 14:00, 23 days 8 hours ago Revive Therapeutics Announce Positive Study Results on Bucillamine for Nerve-Agent Exposure Bucillamine Revive Therapeutics Nerve-agent Research DRDC Study Biodefence
PRESS RELEASE published on 08/12/2026 at 13:55, 23 days 9 hours ago Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study Revive Therapeutics announces positive results from DRDC research study on bucillamine in nerve-agent exposure model, showing preservation of GABA receptors. Further studies planned Bucillamine Revive Therapeutics DRDC Research Study Nerve-agent Exposure GABA Receptors
BRIEF published on 07/16/2026 at 00:45, 1 month 19 days ago Revive Therapeutics Completes First Tranche of Private Placement Private Placement Life Sciences Shares And Warrants Funding Initiative Revive Therapeutics
PRESS RELEASE published on 07/16/2026 at 00:40, 1 month 19 days ago Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement Revive Therapeutics Ltd. closes the first tranche of non-brokered private placement, raising $246,920 for infectious diseases and medical countermeasures research and development Private Placement Research And Development Medical Countermeasures Infectious Diseases Revive Therapeutics Ltd.
Published on 09/04/2026 at 22:30, 29 minutes ago Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 8 hours 29 minutes ago Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Published on 09/04/2026 at 14:00, 8 hours 59 minutes ago Horizon Aircraft Appoints Tom Hearne to Board of Directors and Names Him Audit Committee Chair
Published on 09/04/2026 at 13:30, 9 hours 29 minutes ago Suntex Enterprises Launches Ambitious $1 Billion+ North American Real Estate Development Initiative
Published on 09/04/2026 at 13:00, 9 hours 59 minutes ago Storm Further Upsizes Private Placement to $3.2M
Published on 09/04/2026 at 22:10, 49 minutes ago Quantinuum to Participate in the Bernstein 23rd Annual Pan-European Strategic Decisions Conference
Published on 09/04/2026 at 19:20, 3 hours 39 minutes ago Dahua Technology Showcases Integrated Smart Living and Innovations at IFA Berlin 2026
Published on 09/04/2026 at 18:50, 4 hours 9 minutes ago A&S Resources secures railway funding of USD$6 Billion to unlock $2.5 trillion iron ore asset
Published on 09/04/2026 at 18:05, 4 hours 54 minutes ago Grundig Unveils New Product Lineup at IFA 2026, Marking a New Phase in Strategic Partnership
Published on 09/04/2026 at 18:57, 4 hours 2 minutes ago Disclosure of transactions in own shares from September 1 to September 4, 2026
Published on 09/04/2026 at 17:45, 5 hours 14 minutes ago Declaration of voting rights at the end of August 2026
Published on 09/04/2026 at 17:45, 5 hours 14 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 09/04/2026 at 16:00, 6 hours 59 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2026
Published on 09/04/2026 at 16:00, 6 hours 59 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2026
